These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 36396822)

  • 1. Evolving roles of CD38 metabolism in solid tumour microenvironment.
    Gao L; Du X; Li J; Qin FX
    Br J Cancer; 2023 Feb; 128(4):492-504. PubMed ID: 36396822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers.
    Jiao Y; Yi M; Xu L; Chu Q; Yan Y; Luo S; Wu K
    Expert Opin Investig Drugs; 2020 Nov; 29(11):1295-1308. PubMed ID: 32822558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors.
    Konen JM; Fradette JJ; Gibbons DL
    Cells; 2019 Dec; 9(1):. PubMed ID: 31878283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD38 as an immunotherapeutic target in multiple myeloma.
    Bonello F; D'Agostino M; Moscvin M; Cerrato C; Boccadoro M; Gay F
    Expert Opin Biol Ther; 2018 Dec; 18(12):1209-1221. PubMed ID: 30394809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies.
    Mustafa N; Azaman MI; Ng GGK; Chng WJ
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD38 and ADP-ribosyl cyclase catalyze the synthesis of a dimeric ADP-ribose that potentiates the calcium-mobilizing activity of cyclic ADP-ribose.
    De Flora A; Guida L; Franco L; Zocchi E; Bruzzone S; Benatti U; Damonte G; Lee HC
    J Biol Chem; 1997 May; 272(20):12945-51. PubMed ID: 9148900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADP-Ribosyl cyclase in rat vascular smooth muscle cells: properties and regulation.
    de Toledo FG; Cheng J; Liang M; Chini EN; Dousa TP
    Circ Res; 2000 Jun; 86(11):1153-9. PubMed ID: 10850967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD38 a biomarker and therapeutic target in non-hematopoietic tumors.
    Barrientos-Robledo SG; Cebada-Ruiz JA; Rodríguez-Alba JC; Baltierra-Uribe SL; Díaz Y Orea MA; Romero-Ramírez H
    Biomark Med; 2022 Apr; 16(5):387-400. PubMed ID: 35195042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.
    van de Donk NW; Janmaat ML; Mutis T; Lammerts van Bueren JJ; Ahmadi T; Sasser AK; Lokhorst HM; Parren PW
    Immunol Rev; 2016 Mar; 270(1):95-112. PubMed ID: 26864107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Many Facets of CD38 in Lymphoma: From Tumor-Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy.
    Calabretta E; Carlo-Stella C
    Cells; 2020 Mar; 9(4):. PubMed ID: 32225002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of cyclizing NAD to cyclic ADP-ribose by ADP-ribosyl cyclase and CD38.
    Graeff R; Liu Q; Kriksunov IA; Kotaka M; Oppenheimer N; Hao Q; Lee HC
    J Biol Chem; 2009 Oct; 284(40):27629-36. PubMed ID: 19640843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligation of CD38 suppresses human B lymphopoiesis.
    Kumagai M; Coustan-Smith E; Murray DJ; Silvennoinen O; Murti KG; Evans WE; Malavasi F; Campana D
    J Exp Med; 1995 Mar; 181(3):1101-10. PubMed ID: 7869031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
    Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
    Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting NAD
    Kennedy BE; Sadek M; Elnenaei MO; Reiman A; Gujar SA
    Trends Cancer; 2020 Jan; 6(1):9-12. PubMed ID: 31952784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD38 as an immunomodulator in cancer.
    Li Y; Yang R; Chen L; Wu S
    Future Oncol; 2020 Dec; 16(34):2853-2861. PubMed ID: 32857612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma.
    Duray E; Lejeune M; Baron F; Beguin Y; Devoogdt N; Krasniqi A; Lauwers Y; Zhao YJ; D'Huyvetter M; Dumoulin M; Caers J
    J Hematol Oncol; 2021 Nov; 14(1):183. PubMed ID: 34727950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotaxis of mouse bone marrow neutrophils and dendritic cells is controlled by adp-ribose, the major product generated by the CD38 enzyme reaction.
    Partida-Sanchez S; Gasser A; Fliegert R; Siebrands CC; Dammermann W; Shi G; Mousseau BJ; Sumoza-Toledo A; Bhagat H; Walseth TF; Guse AH; Lund FE
    J Immunol; 2007 Dec; 179(11):7827-39. PubMed ID: 18025229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
    Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
    Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity.
    Hiemstra IH; Santegoets KCM; Janmaat ML; De Goeij BECG; Ten Hagen W; van Dooremalen S; Boross P; van den Brakel J; Bosgra S; Andringa G; van Kessel-Welmers B; Verzijl D; Hibbert RG; Frerichs KA; Mutis T; van de Donk NWCJ; Ahmadi T; Satijn D; Sasser AK; Breij ECW
    EBioMedicine; 2023 Jul; 93():104663. PubMed ID: 37379657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy.
    Horenstein AL; Bracci C; Morandi F; Malavasi F
    Front Immunol; 2019; 10():760. PubMed ID: 31068926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.